# A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Source: https://onco.cc/trials/nct03151811/  
OnCo record `nct03151811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Melphalan flufenamide, Pomalidomide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.

## Summary

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide is a phase 3 interventional study registered as NCT03151811 by Oncopeptides AB, with 495 participants recorded, started 2017-06-12 and due to reach its primary completion in 2021-02-03. Interventions recorded: Melflufen, Pomalidomide, Dexamethasone. Conditions recorded: Multiple Myeloma.

Linked to the drug Melphalan flufenamide because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03151811
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide
- Sponsor: Oncopeptides AB
- Enrolled: 495

## Sources

- ClinicalTrials.gov NCT03151811: https://clinicaltrials.gov/study/NCT03151811

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Melphalan flufenamide](https://onco.cc/drugs/melflufen/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Oncopeptides](https://onco.cc/companies/oncopeptides/)

---
JSON: https://onco.cc/api/v1/entities/nct03151811.json